Predicting Lymph Node Metastasis in Endometrial Cancer Using Serum CA125 Combined with Immunohistochemical Markers PR and Ki67, and a Comparison with Other Prediction Models

Bingyi Yang, Boer Shan, Xiaohong Xue, Huaying Wang, Weiwei Shan, Chengcheng Ning, Qiongjie Zhou, Xiaojun Chen, Xuezhen Luo, Bingyi Yang, Boer Shan, Xiaohong Xue, Huaying Wang, Weiwei Shan, Chengcheng Ning, Qiongjie Zhou, Xiaojun Chen, Xuezhen Luo

Abstract

We aimed to evaluate the value of immunohistochemical markers and serum CA125 in predicting the risk of lymph node metastasis (LNM) in women with endometrial cancer and to identify a low-risk group of LNM. The medical records of 370 patients with endometrial endometrioid adenocarcinoma who underwent surgical staging in the Obstetrics & Gynecology Hospital of Fudan University were collected and retrospectively reviewed. Immunohistochemical markers were screened. A model using serum cancer antigen 125 (CA125) level, the immunohistochemical markers progesterone receptor (PR) and Ki67 was created for prediction of LNM. A predicted probability of 4% among these patients was defined as low risk. The developed model was externally validated in 200 patients from Shanghai Cancer Center. The efficiency of the model was compared with three other reported prediction models. Patients with serum CA125 < 30.0 IU/mL, either or both of positive PR staining > 50% and Ki67 < 40% in cancer lesion were defined as low risk for LNM. The model showed good discrimination with an area under the receiver operating characteristic curve of 0.82. The model classified 61.9% (229/370) of patients as being at low risk for LNM. Among these 229 patients, 6 patients (2.6%) had LNM and the negative predictive value was 97.4% (223/229). The sensitivity and specificity of the model were 84.6% and 67.4% respectively. In the validation cohort, the model classified 59.5% (119/200) of patients as low-risk, 3 out of these 119 patients (2.5%) has LNM. Our model showed a predictive power similar to those of two previously reported prediction models. The prediction model using serum CA125 and the immunohistochemical markers PR and Ki67 is useful to predict patients with a low risk of LNM and has the potential to provide valuable guidance to clinicians in the treatment of patients with endometrioid endometrial cancer.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Flowchart of selection of patients…
Fig 1. Flowchart of selection of patients in prediction cohort.
Fig 2. Performance of the prediction model…
Fig 2. Performance of the prediction model for LNM in endometrial endometrioid cancer.

References

    1. Pelikan HM, Trum JW, Bakers FC, Beets-Tan RG, Smits LJ, Kruitwagen RF Diagnostic accuracy of preoperative tests for lymph node status in endometrial cancer: a systematic review. Cancer Imaging. 2013; 13: 314–322. 10.1102/1470-7330.2013.0032 .
    1. Mariani A, Dowdy SC, Podratz KC New surgical staging of endometrial cancer: 20 years later. Int J Gynaecol Obstet. 2009; 105: 110–111. 10.1016/j.ijgo.2009.02.008 .
    1. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008; 100: 1707–1716. 10.1093/jnci/djn397 .
    1. group As, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009; 373: 125–136. 10.1016/S0140-6736(08)61766-3 .
    1. Walsh CS, Karlan BY Lymphadenectomy's role in early endometrial cancer: prognostic or therapeutic? J Natl Cancer Inst. 2008; 100: 1660–1661. 10.1093/jnci/djn413 .
    1. Seamon LG, Fowler JM, Cohn DE Lymphadenectomy for endometrial cancer: the controversy. Gynecol Oncol. 2010; 117: 6–8. 10.1016/j.ygyno.2009.12.025 .
    1. Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000; 182: 1506–1519. 10.1067/mob.2000.107335 .
    1. Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008; 109: 11–18. 10.1016/j.ygyno.2008.01.023 .
    1. Kang S, Kang WD, Chung HH, Jeong DH, Seo SS, Lee JM, et al. Preoperative identification of a low-risk group for lymph node metastasis in endometrial cancer: a Korean gynecologic oncology group study. J Clin Oncol. 2012; 30: 1329–1334. 10.1200/JCO.2011.38.2416 .
    1. Ballester M, Canlorbe G, Cortez A, Gonin J, Laas E, Bendifallah S, et al. Histological and immunohistochemical profiles predict lymph node status in women with low-intermediate risk endometrial cancer. Gynecol Oncol. 2013; 130: 457–462. 10.1016/j.ygyno.2013.06.001 .
    1. Mitamura T, Watari H, Todo Y, Kato T, Konno Y, Hosaka M, et al. Lymphadenectomy can be omitted for low-risk endometrial cancer based on preoperative assessments. J Gynecol Oncol. 2014. .
    1. Chen X, Zhang Z, Feng Y, Fadare O, Wang J, Ai Z, et al. Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance. Mod Pathol. 2009; 22: 699–708. 10.1038/modpathol.2009.25 .
    1. Boronow RC Surgical staging of endometrial cancer: evolution, evaluation, and responsible challenge—a personal perspective. Gynecol Oncol. 1997; 66: 179–189. 10.1006/gyno.1997.4732 .
    1. Deeks JJ, Altman DG Diagnostic tests 4: likelihood ratios. BMJ. 2004; 329: 168–169. 10.1136/bmj.329.7458.168 .
    1. Nikolaou M, Kourea HP, Tzelepi V, Adonakis G, Scopa CD, Tsapanos V, et al. The prognostic role of preoperative serum CA 125 levels in patients with endometrial carcinoma. J BUON. 2014; 19: 198–202. .
    1. Patsner B, Yim GW Predictive value of preoperative serum CA-125 levels in patients with uterine cancer: The Asian experience 2000 to 2012. Obstet Gynecol Sci. 2013; 56: 281–288. 10.5468/ogs.2013.56.5.281 .
    1. Povolotskaya N, Das N, Dhar K, Brinkmann D, Gardner F, Woolas R Utility of Preoperative CA125 Assay in the Management Planning of Women Diagnosed with Uterine Cancer. Surg Res Pract. 2014; 2014: 497478 10.1155/2014/497478 .
    1. Huang GS, Gebb JS, Einstein MH, Shahabi S, Novetsky AP, Goldberg GL Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am J Obstet Gynecol. 2007; 196: 243.e241–245. 10.1016/j.ajog.2006.09.035 .
    1. Kim CH, Khoury-Collado F, Barber EL, Soslow RA, Makker V, Leitao MM Jr., et al. Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. Gynecol Oncol. 2013; 131: 714–719. 10.1016/j.ygyno.2013.09.027 .
    1. Frumovitz M, Singh DK, Meyer L, Smith DH, Wertheim I, Resnik E, et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol. 2004; 95: 463–468. 10.1016/j.ygyno.2004.07.016 .
    1. Tomisato S, Yamagami W, Susumu N, Kuwahata M, Takigawa A, Nomura H, et al. Clinicopathological study on para-aortic lymph node metastasis without pelvic lymph node metastasis in endometrial cancer. J Obstet Gynaecol Res. 2014; 40: 1733–1739. 10.1111/jog.12399 .
    1. Altay A, Toptas T, Dogan S, Simsek T, Pestereli E Analysis of Metastatic Regional Lymph Node Locations and Predictors of Para-aortic Lymph Node Involvement in Endometrial Cancer Patients at Risk for Lymphatic Dissemination. Int J Gynecol Cancer. 2015; 25: 657–664. 10.1097/IGC.0000000000000392 .

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel